Intravenous (IV) iron drugs market was valued at $2.82 billion in 2025 and is projected to reach $5.38 billion by 2035, registering a CAGR of 6.7% over the forecast period from 2026 to 2035. The market is experiencing significant growth driven by the high and persistent prevalence of iron deficiency and anemia globally, which increases clinical demand for effective therapeutic interventions. Iron deficiency remains the most common nutritional deficiency globally, affecting roughly one in four individuals and contributing substantially to anemia cases that require medical management beyond oral supplementation. IV iron therapies are increasingly used in settings where oral iron is ineffective, poorly tolerated, or too slow to correct severe deficiencies, such as chronic kidney disease and oncology?associated anemia.

The IBS-C drug market was valued at $2.30 billion in 2025 and is projected to reach $3.08 billion by 2035, registering a CAGR of 3.1% over the forecast period from 2026 to 2035. Recent epidemiological research indicates that IBS with constipation (IBS?C) represents a substantial portion of diagnosed IBS cases globally, supporting strong demand for targeted therapies in the IBS?C drug market. A comprehensive meta?analysis using the latest Rome IV criteria found that IBS?C accounted for approximately 34.2% of all IBS cases, reflecting a significant patient population requiring ongoing pharmacological intervention.

The HF acid globe valves market was valued at $460.2 million in 2025 and is projected to reach $909.5 million by 2035, expanding at a CAGR of 7.1% over the forecast period from 2026 to 2035. Refinery safety and regulatory scrutiny surrounding hydrofluoric acid (HF) use in alkylation units has become a major driver for the HF acid globe valves market, as operators seek valves with enhanced containment and fugitive-emission control. Renewed legislative attention, including proposed US federal action to prohibit HF use following concerns about the potential for mass casualty events from HF releases, has highlighted the need for advanced process safety systems. This trend pushes refiners to adopt globe valves engineered for higher reliability and corrosion resistance to support stringent operational protocols and reduce the likelihood of accidental releases.

Guidewires market was estimated at $1.50 billion in 2025 and is expected to reach $2.60 billion by 2035, reflecting a CAGR of 5.8% over the forecast period from 2026 to 2035. Recent product approvals and exclusive distribution agreements are directly strengthening momentum in the peripheral guidewires market. Regulatory clearances enable immediate commercialization of new guidewire technologies, while distribution partnerships expand geographic reach and procedural access within established interventional networks. Together, these developments shorten the path from innovation to clinical use and support faster uptake across hospitals and specialty interventional centres. The focus on longer-length guidewires, transradial access compatibility, and solutions for complex occlusions reflects evolving procedural needs in peripheral arterial and venous interventions.

The furniture market was estimated at $530.2 billion in 2025 and is forecast to reach $793.1 billion by 2035, expanding at a CAGR of 4.2% over the 2026–2035 period. The global furniture market is being shaped by expanding consumption and sustained trade flows in 2024–2025. Across residential and commercial end uses, furniture continues to circulate widely in international commerce and household purchasing. Official customs and trade datasets show that furniture exports from major producing regions remain substantial, reflecting consistent production output and international demand. Movement of furniture goods between economies, including shipments from the European Union, the US, and China, supports broad market activity and underscores furniture’s role as a traded manufactured product. 

Flu shots market reached a value of $9.20 billion in 2025 and is expected to expand to $18.30 billion by 2035, registering a CAGR of 7.2% over the forecast period from 2026 to 2035. The expansion of seasonal influenza vaccination policies and programmes is emerging as a defining trend in the global flu shots market, with wide implications for demand growth and immunization strategy adoption worldwide. Public health authorities, led by the World Health Organization (WHO), are actively encouraging countries to integrate influenza vaccines into national immunization schedules and strengthen coverage among high-risk populations, including older adults, pregnant women, and health workers. As this policy environment evolves, manufacturers and healthcare systems are adjusting production planning and distribution frameworks to meet expanding programme requirements.

Estradiol transdermal patches market was estimated at $1.50 billion in 2025 and is expected to reach $2.46 billion by 2035, registering a CAGR of 5.2% over the forecast period from 2026 to 2035. The global market for estradiol transdermal patches is being shaped by an aging female population facing widespread menopausal symptoms and an ongoing need for effective long?term management of postmenopausal health risks such as osteoporosis. As women enter menopause, the decline in estrogen leads to symptoms that can significantly affect daily functioning and quality of life. 

Digestive health enzymes market was estimated at $660.2 million in 2025 and is forecast to reach $1,121.1 million by 2035, registering a CAGR of 5.6% over the 2026–2035 period. The Global Digestive Health Enzymes market is being driven by the increasing prevalence of digestive disorders, which is translating into heightened demand for enzyme supplementation to support nutrient breakdown and symptom relief. Chronic digestive issues such as lactose intolerance and enzyme insufficiencies are widespread, and many consumers are turning to digestive enzyme products to complement dietary and clinical strategies for managing discomfort. This heightened health need is encouraging manufacturers to innovate and expand product portfolios across enzyme types, align with clean-label preferences, and improve formulation effectiveness. As public awareness grows regarding gut health’s impact on overall wellbeing, digestive enzymes are becoming integrated into preventive health routines as well as therapeutic regimens. The cumulative effect is greater market visibility and stronger uptake of both single-enzyme and multi-enzyme products. According to clinical evidence and health data, a substantial portion of the population experiences digestive enzyme insufficiency or related digestive dysfunction, with global lactase deficiency affecting approximately 75% of adults and pancreatic insufficiency prevalence rising with age, reaching up to 11.5% among older adults in general population studies.

The composite dental bone graft substitute market was valued at $1.35 billion in 2025 and is projected to reach $2.61 billion by 2035, registering a CAGR of 6.9% during the forecast period from 2026 to 2035. The market is being driven by the growing prevalence of severe oral diseases and tooth loss, which directly increases the need for dental implants and bone augmentation procedures. Severe periodontal disease and complete tooth loss remain significant global health challenges, particularly among older adults, creating sustained demand for regenerative solutions that restore bone volume and support implant stability. This health burden compels dental professionals to adopt advanced bone graft substitutes that enhance clinical outcomes in socket preservation, ridge augmentation, and implant site development, strengthening overall market expansion. The trend toward comprehensive oral rehabilitation, especially in aging societies, underscores the strategic importance of composite graft materials that combine favorable biological and handling properties. As dental care systems and clinicians respond to these clinical needs, the substitution of traditional approaches with advanced graft materials is reinforcing long?term market growth.

Beekeeping plastic-coated gloves market was valued at $1.23 billion in 2025 and is expected to reach $1.92 billion by 2035, expanding at a CAGR of 4.7% over the forecast period from 2026 to 2035. The increasing recognition of pollination as a foundational agricultural service has become a key driver for demand in beekeeping protective equipment, including plastic-coated gloves. Bees support the pollination of more than 75% of the world’s food crops, and nearly 90% of wild flowering plant species, underscoring their critical role in global food production and ecological balance. As beekeepers seek to maintain healthy colonies amidst environmental stressors and elevated colony losses, they are placing greater emphasis on protective apparel to safely manage hives. World Bee Day declarations by the United Nations and FAO have further highlighted pollinators’ role in food security, bringing heightened awareness to sustainable beekeeping practices that include the use of reliable protective gear. Supporting this trend, recent data underscores the urgency of maintaining robust bee populations and skilled apiarists: